$69.33
+2.37 (+3.54%)
Open$66.92
Previous Close$66.96
Day High$70.07
Day Low$66.01
52W High$73.30
52W Low$17.11
Volume—
Avg Volume815.9K
Market Cap2.02B
P/E Ratio—
EPS$-0.32
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
-25.3% upside
Current
$69.33
$69.33
Target
$51.79
$51.79
$39.42
$51.79 avg
$66.87
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 243.55M | 82.73M | 183.45M |
| Net Income | -13,736,045 | -118,469,876 | 2.09M |
| Profit Margin | -5.6% | -151.2% | 1.1% |
| EBITDA | -27,000,389 | -141,571,926 | 3.06M |
| Free Cash Flow | — | — | 1.04M |
| Rev Growth | +183.6% | +13.1% | +5.3% |
| Debt/Equity | 7.43 | 4.99 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |